RBC Capital reiterated coverage on Shawcor with a new price target
$SCL
Package Goods/Cosmetics
Consumer Discretionary
RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $8.00 from $9.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/19/2023 | $89.00 | Neutral → Buy | CL King |
| 3/11/2022 | $9.00 → $8.00 | Outperform | RBC Capital |
| 12/20/2021 | $8.50 → $9.00 | Outperform | RBC Capital |
4 - STEPAN CO (0000094049) (Issuer)
4 - STEPAN CO (0000094049) (Issuer)
4 - STEPAN CO (0000094049) (Issuer)
4 - STEPAN CO (0000094049) (Issuer)
4 - STEPAN CO (0000094049) (Issuer)
SC 13G - STEPAN CO (0000094049) (Subject)
SC 13G/A - STEPAN CO (0000094049) (Subject)
SC 13G/A - STEPAN CO (0000094049) (Subject)
NORTHBROOK, Ill., April 14, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) will issue its first quarter 2025 earnings results on Tuesday, April 29, 2025 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 8:00 a.m. ET (7:00 a.m. CT). The call will be hosted by Luis E. Rojo, President and Chief Executive Officer, and Samuel S. Hin
NORTHBROOK, Ill., Feb. 20, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today announced that Edward J. Wehmer has informed the Board of Directors of his decision to retire from the Board as of the date of the Company's next annual meeting of stockholders, which is scheduled for April 29, 2025. Mr. Wehmer will continue to serve on the Company's Board until that date. Mr. Wehmer joined the Company's Board in 2003. He has served as Lead Independent Director since 2016 and served as Chair of the Audit Committee from 2007 to 2023. "Ed has brought his considerable expertise and ta
NORTHBROOK, Ill., Feb. 19, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: Fourth Quarter 2024 Highlights Reported net income was $3.4 million versus a $1.2 million net loss in the prior year. Adjusted net income(1) was $2.8 million, down 63% versus prior year, largely due to higher pre-commissioning expenses at our new alkoxylation investment in Pasadena, Texas ($4.4 million increase), a one-time tax proceeding reserve of $2.9 million recorded in our Latin American operations and higher expenses associated with the previously announced CEO transition in the fou
NORTHBROOK, Ill., April 14, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) will issue its first quarter 2025 earnings results on Tuesday, April 29, 2025 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 8:00 a.m. ET (7:00 a.m. CT). The call will be hosted by Luis E. Rojo, President and Chief Executive Officer, and Samuel S. Hin
NORTHBROOK, Ill., Feb. 19, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: Fourth Quarter 2024 Highlights Reported net income was $3.4 million versus a $1.2 million net loss in the prior year. Adjusted net income(1) was $2.8 million, down 63% versus prior year, largely due to higher pre-commissioning expenses at our new alkoxylation investment in Pasadena, Texas ($4.4 million increase), a one-time tax proceeding reserve of $2.9 million recorded in our Latin American operations and higher expenses associated with the previously announced CEO transition in the fou
NORTHBROOK, Ill., Feb. 19, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.385 per share. The dividend is payable on March 14, 2025, to common stockholders of record on March 3, 2025. The Company increased its quarterly cash dividend in the fourth quarter of 2024 by $0.010 per share, marking the 57th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of specia
CL King upgraded Stepan Company from Neutral to Buy and set a new price target of $89.00
RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $8.00 from $9.00 previously
RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $9.00 from $8.50 previously
NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today announced the appointment of Luis E. Rojo as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. After a 31-year Stepan career, Scott R. Behrens is departing the Company to pursue other opportunities. "We thank Scott for his leadership and his many contributions to the growth and diversification of Stepan over his career with the Company. During his various roles in R&D, sales and marketing, and leadership, he helped diversify our market presence,
NORTHBROOK, Ill., Feb. 15, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) announced today the appointment of Susan M. Lewis as a Director of Stepan, effective on February 15, 2024. Ms. Lewis spent over 30 years at Dow Inc., a materials science company, and was part of the management team of Corteva, Inc., a global agriculture company, following its spinoff from DowDuPont Inc. Ms. Lewis served as Senior Vice President, Global Operations of Corteva from 2018 until her retirement in 2021, after which she worked as a business and executive consultant through 2023. Ms. Lewis held senior management roles with operations, sustainability and risk management responsibilities and led organizational r
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an
DEF 14A - STEPAN CO (0000094049) (Filer)
8-K/A - STEPAN CO (0000094049) (Filer)
10-K - STEPAN CO (0000094049) (Filer)